BusinessCyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140By Nasdaq OMXApr 4, 2017, 5:00 PM UTC
BusinessCyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic PathwaysBy Nasdaq OMXApr 2, 2017, 5:00 PM UTC
